Clinical Trial Update: Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus [Phase 3]

View source ↗

Summary

Phase 3 clinical trial assessing adverse events and changes in disease activity with oral upadacitinib in adults with moderate to severe systemic lupus erythema…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: RECRUITING